Biomerica Inc (BMRA) stock
Close on Nov 12, 2026Market cap $5.98MP/E –Yield –
Biomerica Inc saw revenue fall 11.2% to $4.34M over the twelve months to Aug 31, 2026. At the latest close the market valued the company at $5.98M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Aug 31, 2026
Valuation
- Market cap
- $5.98M
- P/E ratio
- –
- Price to sales
- 1.38
- Price to book
- 1.64
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $4.34M
- Net income
- -$5.01M
- EPS, diluted
- -$1.63
- Book value per share
- $1.11
- Diluted shares
- 3M
Trading
- Previous close
- $1.51
- Open
- $1.52
- Day's range
- $1.27 – $1.52
- Volume
- 30,436
- Average volume (20 days)
- 10,517
- Beta (5 years)
- 0.97
- 52-week range
- $1.27 – $2.94
- RSI (14 days)
- 22.2
- Volatility (1 year)
- 59.0%
- Relative volume
- 0.57×
- WACC
- 9.7%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | BMRA | S&P 500 | Difference | BMRA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -29.2% | -2.7% | −26.5 pts | ||
| 3 months | -17.2% | -1.7% | −15.5 pts | ||
| Year to date | -48.4% | +11.9% | −60.3 pts | ||
| 1 year | -48.4% | +12.0% | −60.4 pts | ||
| 3 years | -82.9% | +78.2% | −161.1 pts | -44.5% | +21.2% |
| 5 years | -96.6% | +73.2% | −169.8 pts | -49.1% | +11.6% |
| 10 years | -91.4% | +309.6% | −401.0 pts | -21.7% | +15.1% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Biomerica filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Biomerica
In Vitro & In Vivo Diagnostic Substances
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures, and markets diagnostic and therapeutic products. Its diagnostic test kits analyze patient blood, urine, nasal, or fecal samples to aid in detecting medical conditions, food intolerances, and diseases such as Helicobacter pylori infections. The company's key product offerings include the inFoods IBS diagnostic-guided therapy test, hp+detect, the EZ Detect colon disease home test, and the Aware Breast Self-Exam product. In addition to diagnostic sales, Biomerica provides contract development and manufacturing organization (CDMO) services to third parties. It primarily serves clinical laboratories, hospitals, medical research institutions, pharmaceutical firms, wholesalers, physicians' offices, drugstores, and point-of-care or over-the-counter retail customers.
Company profile, executives and historyBiomerica stock: common questions
What is Biomerica's stock price?
BMRA closed at $1.30 on Nov 12, 2026, down 13.91% on the day. Over the past 52 weeks it traded between $1.27 and $2.94.
What is Biomerica's market cap?
Biomerica was worth $5.98M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is BMRA's P/E ratio?
Biomerica lost money over the twelve months to Aug 31, 2026 (diluted EPS -$1.63), so it has no meaningful P/E ratio.
How much revenue does Biomerica make?
Biomerica reported revenue of $4.34M for the twelve months to Aug 31, 2026, down 11.2% from a year earlier.
Does Biomerica pay a dividend?
No. Biomerica has not paid a cash dividend over the last twelve months.
How has BMRA stock performed over the past year?
Including dividends, BMRA returned -48.4% over the past year, against +12.0% for the S&P 500.
How many BMRA shares are sold short?
0M shares were sold short at the latest FINRA report, 0.37% of the float, or 1.5 days of average trading volume.
Who are Biomerica's competitors?
Companies most similar to Biomerica by business, industry and size include VNRX, NNNN, IMDX, DYAI, ICCC.
See a number that looks wrong?